177 related articles for article (PubMed ID: 33106918)
1. Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study).
Maruki Y; Morizane C; Arai Y; Ikeda M; Ueno M; Ioka T; Naganuma A; Furukawa M; Mizuno N; Uwagawa T; Takahara N; Kanai M; Asagi A; Shimizu S; Miyamoto A; Yukisawa S; Kadokura M; Kojima Y; Furuse J; Nakajima TE; Sudo K; Kobayashi N; Hama N; Yamanaka T; Shibata T; Okusaka T
J Gastroenterol; 2021 Mar; 56(3):250-260. PubMed ID: 33106918
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
[TBL] [Abstract][Full Text] [Related]
3. Molecular Detection of
Zou Y; Zhu K; Pang Y; Han J; Zhang X; Jiang Z; Huang Y; Gu W; Ji Y
J Clin Transl Hepatol; 2023 Nov; 11(6):1355-1367. PubMed ID: 37719957
[TBL] [Abstract][Full Text] [Related]
4. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
6. FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma.
Wang Y; Shi T; Wang X; Hu J; Yu L; Liu Q; Wu N; Liu B; Wei J
J Transl Med; 2021 Sep; 19(1):401. PubMed ID: 34551773
[TBL] [Abstract][Full Text] [Related]
7. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
[TBL] [Abstract][Full Text] [Related]
8. FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.
Park YS; Na YS; Ryu MH; Lee CW; Park HJ; Lee JK; Park SR; Ryoo BY; Kang YK
Am J Clin Pathol; 2015 Jun; 143(6):865-72. PubMed ID: 25972329
[TBL] [Abstract][Full Text] [Related]
9. FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma.
Huang C; Wen Q; Chen J; Zhong H; Xiang X; Xiong J; Deng J
Cancer Treat Res Commun; 2022; 31():100568. PubMed ID: 35477128
[TBL] [Abstract][Full Text] [Related]
10. FGFR2 Inhibition in Cholangiocarcinoma.
Vogel A; Segatto O; Stenzinger A; Saborowski A
Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
[TBL] [Abstract][Full Text] [Related]
11. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Goyal L; Shi L; Liu LY; Fece de la Cruz F; Lennerz JK; Raghavan S; Leschiner I; Elagina L; Siravegna G; Ng RWS; Vu P; Patra KC; Saha SK; Uppot RN; Arellano R; Reyes S; Sagara T; Otsuki S; Nadres B; Shahzade HA; Dey-Guha I; Fetter IJ; Baiev I; Van Seventer EE; Murphy JE; Ferrone CR; Tanabe KK; Deshpande V; Harding JJ; Yaeger R; Kelley RK; Bardelli A; Iafrate AJ; Hahn WC; Benes CH; Ting DT; Hirai H; Getz G; Juric D; Zhu AX; Corcoran RB; Bardeesy N
Cancer Discov; 2019 Aug; 9(8):1064-1079. PubMed ID: 31109923
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
13. Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population.
Pu XH; Ye Q; Yang J; Wu HY; Ding XW; Shi J; Mao L; Fan XS; Chen J; Qiu YD; Huang Q
Hum Pathol; 2018 Jun; 76():100-109. PubMed ID: 29514108
[TBL] [Abstract][Full Text] [Related]
14. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.
Li F; Peiris MN; Donoghue DJ
Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106
[TBL] [Abstract][Full Text] [Related]
15. Essential role of polymorphism of Gab1, EGFR, and EGF for the susceptibility of biliary tract cancer.
Meng LQ
Tumour Biol; 2014 Dec; 35(12):12497-508. PubMed ID: 25217982
[TBL] [Abstract][Full Text] [Related]
16. Targeted genomic profiling revealed a unique clinical phenotype in intrahepatic cholangiocarcinoma with fibroblast growth factor receptor rearrangement.
Zhu Z; Dong H; Wu J; Dong W; Guo X; Yu H; Fang J; Gao S; Chen X; Lu H; Cong W; Xu Q
Transl Oncol; 2021 Oct; 14(10):101168. PubMed ID: 34252743
[TBL] [Abstract][Full Text] [Related]
17. Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study).
Maruki Y; Morizane C; Arai Y; Ikeda M; Ueno M; Ioka T; Naganuma A; Furukawa M; Mizuno N; Uwagawa T; Takahara N; Kanai M; Asagi A; Shimizu S; Miyamoto A; Yukisawa S; Kadokura M; Kojima Y; Furuse J; Nakajima TE; Sudo K; Kobayashi N; Hama N; Yamanaka T; Shibata T; Okusaka T
J Gastroenterol; 2021 Mar; 56(3):297. PubMed ID: 33377997
[No Abstract] [Full Text] [Related]
18. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue.
Rizzo A; Ricci AD; Frega G; Di Federico A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):567-574. PubMed ID: 33787429
[No Abstract] [Full Text] [Related]
19. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Javle M; Roychowdhury S; Kelley RK; Sadeghi S; Macarulla T; Weiss KH; Waldschmidt DT; Goyal L; Borbath I; El-Khoueiry A; Borad MJ; Yong WP; Philip PA; Bitzer M; Tanasanvimon S; Li A; Pande A; Soifer HS; Shepherd SP; Moran S; Zhu AX; Bekaii-Saab TS; Abou-Alfa GK
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):803-815. PubMed ID: 34358484
[TBL] [Abstract][Full Text] [Related]
20. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer.
Hiraoka N; Nitta H; Ohba A; Yoshida H; Morizane C; Okusaka T; Nara S; Esaki M; Kishi Y; Shimada K
Hum Pathol; 2020 Nov; 105():9-19. PubMed ID: 32891647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
